drugset
drugset / Trial / NCT05328726

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

NCT05328726 ↗

Phase 1 Completed 24 enrolled Gan and Lee Pharmaceuticals, USA
RandomizedParallel-groupDouble-blindTreatment

Summary

Single ascending dose first time in human study for GZR18 in healthy subjects

Timeline

Start
2022-03-08
Primary completion
2023-02-09
Completion
2023-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bofanglutide Protein / enzyme biologic 1 ug/kg Subcutaneous
Subject Bofanglutide Protein / enzyme biologic 5 ug/kg Subcutaneous
Subject Bofanglutide Protein / enzyme biologic 10 ug/kg Subcutaneous
Subject Bofanglutide Protein / enzyme biologic 20 ug/kg Subcutaneous
Subject Bofanglutide Protein / enzyme biologic 30 ug/kg Subcutaneous
Subject Bofanglutide Protein / enzyme biologic 40 ug/kg Subcutaneous
Subject Bofanglutide Protein / enzyme biologic 50 ug/kg Subcutaneous

Indications

type 2 diabetes mellitus